Status:
ENROLLING_BY_INVITATION
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Lead Sponsor:
AbbVie
Conditions:
Neovascular Age-Related Macular Degeneration (nAMD)
Gene Therapy
Eligibility:
All Genders
Brief Summary
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD i...
Eligibility Criteria
Inclusion
- Must provide written, signed informed consent for this study.
- Must have been enrolled in a previous clinical study of RGX-314 in the treatment of nAMD and must have received an SCS injection of RGX-314 in that study.
- Must be willing and able to comply with all study procedures.
Exclusion
- 1\. None
Key Trial Info
Start Date :
December 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT05210803
Start Date
December 20 2021
End Date
March 1 2028
Last Update
June 18 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Retinal Research Institute, LLC
Phoenix, Arizona, United States, 85014
2
California Retina Consultants
Bakersfield, California, United States, 93309
3
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
4
Northern California Retina Vitreous Associates Medical Group Inc
Mountain View, California, United States, 94040